-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Effector T cell stimulation is an attractive immunotherapy method in oncology
.
OX40 (CD134) is a costimulatory receptor expressed on activated CD4+ and CD8+ T cells
immunity
Ivuxolimab (PF-04518600) is a fully human immunoglobulin G2 agonistic monoclonal antibody specific for human OX40
.
This article reports the results of the single-dose escalation part of a multicenter phase I clinical trial of Ivuxolimab
52 screened adult patients with locally advanced or metastatic cancer received 0.
01-10 mg/kg of Ivuxolimab
.
The primary endpoint is safety and tolerability
The most common all-cause adverse reactions were fatigue (46.
2%), nausea (28.
8%) and loss of appetite (25.
0%)
.
Of the 31 treatment-related adverse reactions, 30 (96.
The most common all-cause adverse reactions were fatigue (46.
Expression changes of OX40 at different doses
Three patients (5.
8%) achieved partial remission, and 56% achieved disease control
.
Increased proliferation and activation of CD4+ central memory T cells, as well as the clonal expansion of CD4+ and CD8+ T cells in peripheral blood, were observed at doses of 0.
Three patients (5.
Correlation between tumor progression and OX40 expression
In summary, the targeted immune activation of Ivuxolimab at clinically relevant doses is usually well tolerated, and has shown preliminary anti-tumor activity, which can be used as one of the drugs studied in the joint program
.
It can be used as one of the drugs studied in the joint program
.
Ivuxolimab's targeted immune activation at clinically relevant doses is usually well tolerated and has shown preliminary anti-tumor activity.
Original source:
Adi Diab, Omid Hamid, John A.
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers in this message
